A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

计划入组 110 人 · 首次发布于 2024 年 11 月 21 日

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

计划入组 240 人 · 首次发布于 2025 年 3 月 30 日

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

计划入组 101 人 · 首次发布于 2020 年 6 月 4 日

CLS-122

CLS-007

CLS-3

CLS PHARMA

France

Olink Holding AB

Sweden

Meda AB

Sweden

Calico's ABBV-CLS-628 Receives FDA Fast Track Designation for Autosomal Dominant Polycystic Kidney Disease

ClearPoint Neuro's MR-Guided Laser Therapy Shows Promise for Brain Cancer Treatment in Phase I-II Study

AbbVie Terminates $3.5 Billion Calico Partnership After 11 Years, Cuts 100 Jobs